NCT07413835

Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of HN2302 in Patients With Refractory Myasthenia Gravis

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: The Affiliated Hospital of Xuzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, single arm study, to evaluate the safety , tolerability and preliminary efficacy of HN2302 for refractory myasthenia gravis.

Detailed description

The study will consist of an up to 4-week Screening Period, Treatment Period and one year Follow-up Period.

Conditions

• Refractory Myasthenia Gravis

Interventions

Type	Name	Description
DRUG	HN2302 Injection	Patients will be administrated with specified dose on specified days at a lower dose level and escalated to safe and effective dose levels.

Timeline

• Start date: 2026-03-17
• Primary completion: 2027-06-01
• Completion: 2027-12-01
• First posted: 2026-02-17
• Last updated: 2026-03-18

Locations

1 site across 1 country: China